上海交通大学学报（医学版）

上海交通大学学报（医学版） ›› 2017, Vol. 37 ›› Issue (9): 1297-.doi: 10.3969/j.issn.1674-8115.2017.09.019?

• 综述 • 上一篇    下一篇

可溶性血管内皮生长因子受体-1在年龄相关性黄斑变性中的 作用和应用前景#br#

肖美春，王晓寒，汪枫桦   

  1. 上海交通大学附属第一人民医院眼科，上海 200080
  • 出版日期:2017-09-28 发布日期:2017-10-10
  • 通讯作者: 汪枫桦，电子信箱：shretina@sjtu.edu.cn
  • 作者简介:肖美春（1991—），女，硕士生；电子信箱：cynthiaxiao1@163.com
  • 基金资助:
     国家自然科学基金（81300820）；上海市教育委员会高峰高原学科建设计划（20152229）

Function and application of soluble vascular endothelial growth factor receptor-1 in age-related macular degeneration#br#

XIAO Mei-chun, WANG Xiao-han, WANG Feng-hua   

  1. Department of Ophthalmology, Shanghai General Hospital, Shanghai Jiao Tong University, Shanghai 200080, China
  • Online:2017-09-28 Published:2017-10-10
  • Supported by:
    National Natural Science Foundation of China,81300820; Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant Support, 20152229

PDF (PC)

819

摘要： 年龄相关性黄斑变性（AMD）是 50 岁以上老年人重要致盲眼病。血管内皮生长因子（VEGF）与湿性 AMD 发生发展密切相 关，目前主要采用针对VEGF 的单克隆抗体药物治疗，但维持时间短，需要频繁、重复治疗。随着基因治疗的发展，可能作为生物 标志物的可溶性血管内皮生长因子受体 -1（sFlt-1）逐渐受到关注。sFlt-1 是目前发现唯一的内源性 VEGF 抑制剂。在 AMD 发展过程 中，患者血清 sFlt-1 水平明显降低。该文就近年来有关 sFlt-1 的分子结构、病理生理学功能、在 AMD 发生发展中的作用、临床前研 究及临床研究进行综述。

关键词: 可溶性血管内皮生长因子受体 -1, 血管内皮生长因子, 年龄相关性黄斑变性, 基因治疗

Abstract:

Age-related macular degeneration (AMD) is the leading cause of blindness in people over 50 years old. Vascular endothelial growth factor (VEGF) plays a critical role in the development of wet AMD. At present, the main treatment is monoclonal antibodies against VEGF, but the maintenance time is short, and it requires frequent and repeated treatment. Recently with the fast development of gene therapy, soluble VEGF receptor -1 (sFlt-1), which may act as one of the biomarkers of AMD, is gaining more attention. sFlt-1 is the unique endogenous VEGF inhibitor. With the development of AMD, serum sFlt-1 decreases markedly. This article reviewed the molecular structure and pathophysiological function of sFlt-1, its role in the advance of AMD, and the preclinical studies as well as clinical studies about it.

Key words: soluble vascular endothelial growth factor receptor-1, vascular endothelial growth factor, age-related macular degeneration, gene therapy